<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29366" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Spiradenoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Miceli</surname>
            <given-names>Alyssa</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ferrer-Bruker</surname>
            <given-names>Sarah J.</given-names>
          </name>
          <aff>VCOM/Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alyssa Miceli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Ferrer-Bruker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29366.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Spiradenomas are well-differentiated, benign, dermal neoplasms originating from the sweat glands. Most spiradenomas occur between the ages of 15 to 35 years. Typically, they present as small solitary nodules that can grow to several centimeters, often with a blue, gray, or purple hue. They are very painful. Spiradenomas usually arise on the head, neck, and trunk; however, cases in other areas such as the breast have occurred. Although spiradenomas are considered benign adnexal neoplasms with low recurrence rates, malignant transformation can occur in long-standing lesions, particularly in patients older than the age of 50. Conservative surgical excision of spiradenomas is therefore recommended. This activity reviews the presentation, evaluation, and management of spiradenomas and highlights the role of an interprofessional team approach.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of spiradenomas.</p></list-item><list-item><p>Evaluate&#x000a0;the clinical presentation of a spiradenoma.</p></list-item><list-item><p>Determine&#x000a0;the treatment and management options for spiradenomas.</p></list-item><list-item><p>Communicate the importance of improving coordination amongst the interprofessional team to enhance care for patients affected by spiradenomas.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29366&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29366">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29366.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Spiradenomas are well-differentiated, benign, dermal neoplasms originating from the sweat glands. Most spiradenomas occur between the ages of 15 to 35 years. Typically, they present as small solitary nodules that can grow to several centimeters, often with a blue, gray, or purple hue.<xref ref-type="bibr" rid="article-29366.r1">[1]</xref>&#x000a0;They are strikingly painful. Spiradenomas usually arise on the head, neck, and trunk; however, cases have occurred in other areas, such as the breast. Spiradenomas with varying morphology, like multiple linear, zosteriform, blaschkoid, and nevoid spiradenomas, have also been reported. Spiradenomas can occur concomitantly with cylindromas, trichoepitheliomas, or trichoblastomas. Multiple spiradenomas, cylindromas, and trichoepitheliomas can be seen in patients with Brooke-Spiegler.<xref ref-type="bibr" rid="article-29366.r2">[2]</xref></p>
      </sec>
      <sec id="article-29366.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Spiradenomas appear to be caused by a defective tumor suppressor gene. A mutation in the&#x000a0;<italic toggle="yes">CYLD</italic>&#x000a0;gene on chromosome&#x000a0;16 is found in Brooke-Spiegler syndrome, which features multiple spiradenomas.<xref ref-type="bibr" rid="article-29366.r3">[3]</xref>&#x000a0;The specific cause of solitary spiradenomas is not clear. Originally thought to be of eccrine differentiation, recent studies have suggested that spiradenomas may be derived from apocrine glands or the folliculosebaceous unit.</p>
        <p>The cause of malignant spiradenomas is also unknown. Increased expression of p53 is seen, though the significance&#x000a0;of this finding in the malignant transformation of spiradenomas has not been determined.<xref ref-type="bibr" rid="article-29366.r4">[4]</xref></p>
      </sec>
      <sec id="article-29366.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Spiradenomas are usually benign and most often occur in patients between 15 and 35, though cases have been reported in infants. There is no racial or sexual predilection for spiradenomas. To date, approximately 15 cases of either linear, zosteriform, nevoid, blaschkoid, or multiple spiradenomas have been reported in the literature.<xref ref-type="bibr" rid="article-29366.r5">[5]</xref><xref ref-type="bibr" rid="article-29366.r6">[6]</xref><xref ref-type="bibr" rid="article-29366.r7">[7]</xref> Although benign spiradenomas are quite&#x000a0;rare, malignant spiradenomas are even rarer and occur in patients older than the age of 50 years, with an average age of 59 years.<xref ref-type="bibr" rid="article-29366.r8">[8]</xref></p>
      </sec>
      <sec id="article-29366.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of the formation of spiradenomas is not completely&#x000a0;understood. A defect in the tumor suppressor gene, CYLD<italic toggle="yes">,&#x000a0;</italic>is thought to contribute to their development in Brooke-Spiegler syndrome, which also features multiple cylindromas.<xref ref-type="bibr" rid="article-29366.r3">[3]</xref> A&#x000a0;transition between cylindromas and spiradenomas has been shown to occur in patients with&#x000a0;CYLD&#x000a0;gene mutations. Derangements in intercellular bridge proteins that maintain epithelial organization, including claudin-4, cadherin, and beta-catenin,&#x000a0;have also been suggested to contribute to neoplasm formation.<xref ref-type="bibr" rid="article-29366.r9">[9]</xref>&#x000a0;Two studies found intense nuclear immunoreactivity for beta-catenin in spiradenomas, supporting the role of alterations in the beta-catenin pathway in their development. Professionals postulate that an abnormal clone arising during embryogenesis produces multiple abnormal cells that result&#x000a0;in presentations involving multiple nevoid, blaschkoid, or linear spiradenomas.</p>
        <p>Historically, spiradenomas were thought to be of eccrine lineage, though many lesions have been shown to demonstrate apocrine differentiation.&#x000a0;Alternatively,&#x000a0;1 study using immunohistochemical markers for stem cells and CD200 suggests that spiradenomas and cylindromas are follicular-based tumors instead of derived from eccrine or apocrine glands. Other studies have shown spiradenomas to have either apocrine or folliculosebaceous differentiation.<xref ref-type="bibr" rid="article-29366.r10">[10]</xref>&#x000a0;Increased expression of p53 has been observed in malignant spiradenomas.<xref ref-type="bibr" rid="article-29366.r11">[11]</xref></p>
      </sec>
      <sec id="article-29366.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>On histopathology, spiradenomas show&#x000a0;1 or more large, sharply demarcated basophilic nodules of the dermis. Two types of cells are seen in the nodules. These cells are either&#x000a0;small, dark, basaloid cells with hyperchromatic nuclei or larger, pale, and with ovoid nuclei. These lighter cells tend to be toward the center of the lesion. Duct-like structures of uninterpretable differentiation and cystic cavities filled with finely granular eosinophilic material may be seen.<xref ref-type="bibr" rid="article-29366.r12">[12]</xref><xref ref-type="bibr" rid="article-29366.r13">[13]</xref>&#x000a0;The material within the cystic cavities is diastase resistant and periodic acid-Schiff positive. A lymphangiectatic variant has rarely been described.&#x000a0;Immunohistochemical staining shows increased expression of S-100 in the large, pale-staining cells and human milk fat globulin (HMFG) and lysozyme in the tubular cells.<xref ref-type="bibr" rid="article-29366.r10">[10]</xref> Spiradenomas also stain positive for epithelial membrane antigen, carcinoembryonic antigen, and the myoepithelial stains p63 and SMA. The cytokeratin patterns include expression of keratins 7, 8, 14, and 18.<xref ref-type="bibr" rid="article-29366.r14">[14]</xref><xref ref-type="bibr" rid="article-29366.r15">[15]</xref></p>
        <p>Malignant spiradenomas demonstrate increased mitotic rates, necrosis, nuclear atypia, pleomorphism, hyperchromasia, loss of nested growth patterns, and loss of the dual cell population. In histologic studies, two patterns of malignant spiradenomas were observed. One was an abrupt transition between a benign spiradenoma and high-grade carcinoma, while the second showed contiguity between the benign and malignant areas.</p>
      </sec>
      <sec id="article-29366.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Spiradenomas typically present as dermal or subcutaneous nodules on any area, though more commonly seen on the head, neck, and trunk and less commonly on the arms and legs. Several spiradenomas have been reported on the ears, eyelids, and papular lesions of the proximal nail fold. On physical examination, lesions are typically small, though they can grow to several centimeters in diameter and have a blue, gray, or purple hue. Spiradenomas can be strikingly painful, though most are asymptomatic. Although the typical presentation is a solitary lesion, there can be linear, blaschkoid, or grouped spiradenomas. Multiple spiradenomas can be seen, and if present with cylindromas and trichoblastomas, Brooke-Spiegler syndrome must be considered.<xref ref-type="bibr" rid="article-29366.r16">[16]</xref>&#x000a0;Based on the physical exam, the differential diagnosis of spiradenomas typically includes cylindromas, epidermal inclusion cysts, dermatofibromas, leiomyomas, poromas, and basal cell carcinomas.</p>
        <p>Though rare, spiradenomas have occurred in infancy, representing less than 1% of all reported cases of spiradenoma. These typically present as more superficial dermal nodules than seen in adults.</p>
        <p>Rapid growth in a long-standing lesion may indicate malignant transformation. Malignant spiradenomas also tend to ulcerate and have a predilection for the trunk and extremities. A change in the lesion's color can signify malignant transformation. Metastases from malignant spiradenomas can occur in lymph nodes, the lungs, the brain, or the liver.</p>
      </sec>
      <sec id="article-29366.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Lesions should be excised for histopathologic examination. On histopathology, spiradenomas show&#x000a0;1 or more large, sharply demarcated basophilic nodules of the dermis. Two types of cells are seen in the nodules. These cells are either&#x000a0;small, dark, basaloid cells with hyperchromatic nuclei or larger, pale, and with ovoid nuclei.&#x000a0;Malignant spiradenomas demonstrate increased mitotic rates, necrosis, nuclear atypia, pleomorphism, hyperchromasia, loss of nested growth patterns, and loss of the dual cell population.<xref ref-type="bibr" rid="article-29366.r4">[4]</xref>&#x000a0;Imaging studies, including MRI, CT, or ultrasound, can help determine if metastatic foci are present in malignant spiradenoma.</p>
      </sec>
      <sec id="article-29366.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Although spiradenoma is considered a benign adnexal neoplasm with a low recurrence rate, malignant transformation can occur in long-standing lesions, particularly in patients older than 50.&#x000a0;The rate of metastasis for malignant spiradenocarcinoma is about 50%.&#x000a0;Conservative surgical excision of spiradenomas is therefore recommended. In cases of multiple spiradenomas, adjunctive treatment with a carbon dioxide laser may be employed after surgical debulking.</p>
        <p>Malignant spiradenomas tend to be aggressive tumors with high rates of metastasis and mortality. Radiation and chemotherapy may be used after tumor resection for malignant spiradenomas.</p>
      </sec>
      <sec id="article-29366.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for&#x000a0;spiradenoma&#x000a0;include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Angiolipoma</p>
          </list-item>
          <list-item>
            <p>Dermatofibroma</p>
          </list-item>
          <list-item>
            <p>Epidermal inclusion cyst</p>
          </list-item>
          <list-item>
            <p>Leiomyoma</p>
          </list-item>
          <list-item>
            <p>Poroma</p>
          </list-item>
          <list-item>
            <p>Schwannoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29366.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dermatologists often coordinate care with other specialists as well as primary care physicians. Dermatologists are trained in clinical and dermatopathology, making clinicopathologic correlation a crucial part of dermatologists' management of cutaneous conditions. Given this unique training, it is important for dermatologists to effectively communicate with primary care and other specialty physicians about the proper management of both benign and malignant cutaneous neoplasms. This collaborative decision-making provides the best care and outcomes for patients. &#x000a0;In the case of spiradenomas, though a benign neoplasm, complete surgical excision is recommended, given the potential for malignant transformation. With proper evidence-based management, the risk for this malignant transformation diminishes, improving the long-term prognosis for the patient.</p>
      </sec>
      <sec id="article-29366.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29366&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29366">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/spiradenoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29366">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29366/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29366">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29366.s13">
        <title>References</title>
        <ref id="article-29366.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaleeswaran</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Janaki</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Sentamilselvi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kiruba</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Eccrine spiradenoma.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2002</year>
            <season>Jul-Aug</season>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>236</fpage>
            <page-range>236-7</page-range>
            <pub-id pub-id-type="pmid">17656951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bumgardner</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nunez-Gussman</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Trichoepitheliomas and eccrine spiradenomas with spiradenoma/cylindroma overlap.</article-title>
            <source>Int J Dermatol</source>
            <year>2005</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>415</fpage>
            <page-range>415-7</page-range>
            <pub-id pub-id-type="pmid">15869542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohiuddin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cruse</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Brooke-Spiegler Syndrome.</article-title>
            <source>Eplasty</source>
            <year>2018</year>
            <volume>18</volume>
            <fpage>ic14</fpage>
            <pub-id pub-id-type="pmid">30093932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Mercer</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Phelps</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Histological findings and pathologic diagnosis of spiradenocarcinoma: A case series and review of the literature.</article-title>
            <source>J Cutan Pathol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-250</page-range>
            <pub-id pub-id-type="pmid">30588645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bounniyt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>El Amraoui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benzekri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Senouci</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hassam</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Malignant transformation of a spiradenoma with blaschko&#x000ef;d pattern.</article-title>
            <source>Clin Case Rep</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>2086</fpage>
            <page-range>2086-2088</page-range>
            <pub-id pub-id-type="pmid">30455896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosales Santillan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>ATajnert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Swaby</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Migden</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Silapunt</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Multiple eccrine spiradenomas in a zosteriform pattern.</article-title>
            <source>Dermatol Online J</source>
            <year>2017</year>
            <month>Aug</month>
            <day>15</day>
            <volume>23</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">29469747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agnihotri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kothari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>&#x003a8; Multiple eccrine spiradenomas with a zosteriform pattern-Report of a rare case diagnosed on fine needle aspiration cytology.</article-title>
            <source>Diagn Cytopathol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>9</issue>
            <fpage>832</fpage>
            <page-range>832-833</page-range>
            <pub-id pub-id-type="pmid">28556514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ezaldein</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Bordeaux</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Trends in the incidence and survival of eccrine malignancies in the United States: A SEER population-based study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>1769</fpage>
            <page-range>1769-1771</page-range>
            <pub-id pub-id-type="pmid">30287321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Im</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Alteration of the &#x003b2;-catenin pathway in spiradenoma.</article-title>
            <source>J Cutan Pathol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>657</fpage>
            <page-range>657-62</page-range>
            <pub-id pub-id-type="pmid">21518380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meybehm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>HP</given-names>
              </name>
            </person-group>
            <article-title>Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations.</article-title>
            <source>Am J Dermatopathol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>154</fpage>
            <page-range>154-61</page-range>
            <pub-id pub-id-type="pmid">9129700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Calonje</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Busam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Malignant eccrine spiradenoma (spiradenocarcinoma): a clinicopathologic study of 12 cases.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-103</page-range>
            <pub-id pub-id-type="pmid">10770427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>DeFelice</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Spiradenomas.</article-title>
            <source>Dermatol Online J</source>
            <year>2012</year>
            <month>Dec</month>
            <day>15</day>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">23286805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanwaljeet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Eccrine spiradenoma: A rare adnexal tumor.</article-title>
            <source>Indian J Cancer</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>695</fpage>
            <page-range>695-696</page-range>
            <pub-id pub-id-type="pmid">30082561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Missall</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Burkemper</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Immunohistochemical differentiation of four benign eccrine tumors.</article-title>
            <source>J Cutan Pathol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-6</page-range>
            <pub-id pub-id-type="pmid">18564284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurokawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tarumi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hakamada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Isoda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mizutani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsubura</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Eccrine spiradenoma: co-expression of cytokeratin and smooth muscle actin suggesting differentiation toward myoepithelial cells.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>121</fpage>
            <page-range>121-3</page-range>
            <pub-id pub-id-type="pmid">17207189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29366.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Brooke-Spiegler syndrome associated with cylindroma, trichoepithelioma and eccrine spiradenoma.</article-title>
            <source>Int J Dermatol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>12</issue>
            <fpage>1602</fpage>
            <page-range>1602-4</page-range>
            <pub-id pub-id-type="pmid">24261740</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
